Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.21.1
Consolidated Statements of Operations - USD ($)
shares in Thousands
 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue $ 29,947,000 $ 29,956,000
Cost of revenue 19,875,000 20,309,000
Gross profit 10,072,000 9,647,000
Operating expenses    
Research and development 4,032,000 5,346,000
Sales and marketing 5,207,000 7,592,000
General and administrative 4,086,000 4,757,000
Intangibles amortization 903,000 1,233,000
Restructuring 0 234,000
Long-lived assets impairment 525,000 1,007,000
Total operating expenses 14,753,000 20,169,000
Operating income (loss) (4,681,000) (10,522,000)
Gain (Loss) on Extinguishment of Debt 1,637,000  
Other income (expense), net 288,000 456,000
Income (loss) before income taxes (2,756,000) (10,066,000)
Income tax (expense) benefit 22,000 (36,000)
Net income (loss)(1) [1] $ (2,734,000) $ (10,102,000)
Basic net income (loss) per share:    
Earnings Per Share, Basic $ (0.20) $ (0.65)
Earnings Per Share, Diluted [Abstract]    
Earnings Per Share, Diluted $ (0.20) $ (0.65)
Weighted-average number of shares outstanding:    
Basic 13,340 15,530
Effect of dilutive securities: restricted stock, restricted stock units, performance stock units and stock options(2) [2] 0 0
Diluted 13,340 15,530
[1] Net income (loss) and comprehensive income (loss) are the same for the periods reported.
[2] The Company has 0.8 million and 0.9 million shares represented by common stock equivalents for the twelve months ended March 31, 2021 and 2020, respectively, which were not included in the computation of average dilutive shares outstanding because they were anti-dilutive. In periods with a net loss from continuing operations, the basic loss per share equals the diluted loss per share as all common stock equivalents are excluded from the per share calculation because they are anti-dilutive.